BNT411 is a toll-like receptor 7 (TLR7) agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune …

Background The intravenously administered small-molecule Toll-like receptor 7 (TLR7) agonist BNT411 was developed to systemically activate plasmacytoid dendritic cells, characterized by …

BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell …

BNT411 is a toll-like receptor 7 (TLR7) agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune …

A Toll-like receptor (TLR) 7 agonist with potential immunostimulating and antitumor activities. Upon administration, TLR7 agonist BNT411 binds to and activates TLR7.

2021年8月1日 · Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral …

Upon administration, TLR7 agonist BNT411 binds to and activates TLR7. This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells, …

BNT 411 is a small molecule toll-like receptor 7 (TLR7) agonist being developed by BioNTech for the treatment of solid tumours including small cell lung cancer.

BNT411 is a TLR7 agonist, which activates B cells and CD8-positive T-lymphocytes as well as innate immune cells, potentially resulting in antitumor activity (NCI Drug Dictionary). Separate …

BNT-411是由Biontech Se研发的一种小分子药物，是一种TLR7激动剂。 目前该药物最高研发阶段为终止，用于治疗实体瘤和小细胞肺癌。 BNT-411-靶点: TLR7_适应症-临床_专利_批准